Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00996957 · ClinicalTrials.gov registry record · Phase 1

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma and Advanced Solid Tumors, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ U.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target
4
Study locations

NCT00996957 is a Phase 1 study of Multiple Myeloma and Advanced Solid Tumors that has completed, run by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ U. The registered enrollment target is 37 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00996957, a Phase 1 study of Multiple Myeloma and Advanced Solid Tumors, has completed, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ U.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target
4
Study locations

Study Summary

For cancer cells to grow, they need to have nutrients supplied to them through blood vessels. The study drug, ACE-041, is designed to work by blocking the growth of those blood vessels and preventing cancer cells from growing. The purpose of this study is to establish safe dose levels of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma following multiple dose administration. This study will also evaluate if ACE-041 has an effect on tumors.

Conditions Studied

Multiple Myeloma Advanced Solid Tumors

Interventions

  • BIOLOGICAL ACE-041

Study Locations (4)

Arizona

  • Acceleron Investigative Site - Scottsdale

North Carolina

  • Acceleron Investigative Site - Durham

Tennessee

  • Acceleron Investigative Site - Nashville

Utah

  • Acceleron Investigative Site - Salt Lake City

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2009-10
Est. Completion 2012-10
Phase Phase 1

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ U

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00996957

The ClinicalTrials.gov registry entry for NCT00996957 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ U, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which ACE-041 is the first listed.

NCT00996957 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, North Carolina, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00996957 about?

NCT00996957 is a clinical study titled "Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma". For cancer cells to grow, they need to have nutrients supplied to them through blood vessels. The study drug, ACE-041, is designed to work by blocking the growth of those blood vessels and preventing cancer cells from growing. The purpose of this study is to establish safe dose levels of ACE-041 in ...

What is the current status of trial NCT00996957?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2009-10. Estimated completion is 2012-10.

What conditions does trial NCT00996957 study?

This clinical trial studies the following conditions: Multiple Myeloma, Advanced Solid Tumors.

What interventions are being tested in trial NCT00996957?

The interventions under investigation include: ACE-041 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00996957?

This trial is sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ U, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00996957 being conducted?

This trial has 4 study locations across Arizona, North Carolina, Tennessee, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Advanced Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.